CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
78 (est)
Website
cytomx.com
CytomX Therapeutics was founded in 2008 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at CytomX Therapeutics

D. Sean A. McCarthy

D. Sean A. McCarthy

President and Chief Executive Officer
Rachel Humphrey

Rachel Humphrey

Chief Medical Officer
Sridhar Viswanathan

Sridhar Viswanathan

Senior Vice President, Process Sciences and Manufacturing Operations
W. Kavanaugh

W. Kavanaugh

Chief Scientific Officer and Head of Research and Non-Clinical Development
Danielle Olander

Danielle Olander

Senior Vice President, Talent and Administrative Operations
Carol Verser

Carol Verser

Vice President, Intellectual Property
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd
Show all (1)
Report incorrect company information

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Financials

CytomX Therapeutics's revenue was reported to be $71.62 m in FY, 2017
USD

Revenue (Q1, 2018)

14.2 m

Net income (Q1, 2018)

(15.5 m)

EBIT (Q1, 2018)

(15.6 m)

Market capitalization (21-May-2018)

957.2 m

Closing share price (21-May-2018)

24.6

Cash (31-Mar-2018)

142.2 m
CytomX Therapeutics's current market capitalization is $957.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

7.7 m15 m71.6 m

Revenue growth, %

95%

General and administrative expense

25.6 m

R&D expense

92.3 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

1.9 m1.8 m2.5 m2.8 m11.2 m8.3 m23.7 m14.2 m

General and administrative expense

4.1 m5 m4.6 m5 m5.7 m6 m7.4 m

R&D expense

9.2 m13.4 m12.7 m13.3 m14.6 m28.1 m22.5 m

Operating expense total

13.2 m18.4 m17.4 m18.4 m20.3 m34.1 m35.2 m29.8 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

59.8 m104.6 m177.5 m

Accounts Receivable

744 k2.2 m10.1 m

Inventories

2.3 m3.9 m

Current Assets

189.8 m188.1 m388.6 m
Quarterly
USDQ3, 2017Q1, 2018

Cash

142.2 m

Accounts Receivable

40.2 m81 k

Inventories

4.8 m

Current Assets

367 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(35.4 m)(58.9 m)(43.1 m)

Depreciation and Amortization

1.2 m1.7 m1.6 m

Accounts Payable

2.9 m1.8 m(2.4 m)

Cash From Operating Activities

(27.4 m)(2 m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.9 m)(16 m)(14.2 m)(14.7 m)(8.3 m)(10.2 m)

Inventories

4.8 m

Accounts Payable

2.7 m5 m1.4 m517 k3.7 m6.4 m2.9 m
USDY, 2018

Financial Leverage

7.6 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (foreign)

4

Patents Pending

144

Phase I Trials Products

1

Preclinical Phase Products

4
Show all operating metrics
Report incorrect company information